Chair of the Panel:

Usama Abdel Naseer

➡️Scientific Group Members:

Abdalla Anayet, Abdelrahman Eltahaan, Ahmed Mostafa, Alaa Gaafar, Amr Taha, Ashraf Lotfy, Athar Reda Ibrahim, Bahaa Eltoukhy, Haytham Elfarargy, Hazem Dewidar, Ihab Sifin, Loay Elsharkawy, Mai Mohammed Salama, Mina Esmat, Rania Abdou, Reda Sharkawy, Saad Elzayat, Samir Halim.

➡️Abbreviations

AR: Allergic rhinitis

INC: Intranasal corticosteroid

LTRA: Oral leukotriene receptor antagonist

PAR: Perennial allergic rhinitis

RCT: andomized controlled trial

SAR: Seasonal allergic rhinitis

➡️Glossary

- Allergic rhinitis (AR): Disease caused by an IgE-mediated inflammatory response of the nasal mucous membranes after exposure to inhaled allergens. Symptoms include rhinorrhea (anterior or posterior nasal drainage), nasal congestion, nasal itching, and sneezing.

- Seasonal allergic rhinitis (SAR): Disease caused by an IgE-mediated inflammatory response to seasonal aeroallergens. The length of seasonal exposure to these allergens is dependent on geographic location and climatic conditions.

- Perennial allergic rhinitis (PAR): Disease caused by an IgE-mediated inflammatory response to year-round environmental aeroallergens. These may include dust mites, mold, animal allergens, or certain occupational allergens.

- Intermittent allergic rhinitis: Disease caused by an IgE-mediated inflammatory response and characterized by frequency of exposure or symptoms (<4 days per week or <4 weeks per year).

- Persistent allergic rhinitis: Disease caused by an IgE-mediated inflammatory response and characterized by persistent symptoms (>4 days per week and >4 weeks per year).

- Episodic allergic rhinitis: Disease caused by an IgE-mediated inflammatory response that can occur if an individual is in contact with an exposure that is not normally a part of the individual’s environment. (ie, a cat at a friend’s house).

➡️Scope

This Guideline is concerned with diagnosis and treatment decision of allergic rhinitis, and reduce harmful or unnecessary variations in care. The guideline is intended to be applicable for both pediatric and adult patients with AR. Children under the age of 2 years were excluded because rhinitis in this population may be different than in older patients and is not informed by the same evidence base.